These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22151689)

  • 1. Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study.
    Berger A; Edelsberg J; Bollu V; Alvir JM; Dugar A; Joshi AV; Oster G
    BMC Psychiatry; 2011 Dec; 11():193. PubMed ID: 22151689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study.
    Berger A; Edelsberg J; Treglia M; Alvir JM; Oster G
    BMC Psychiatry; 2012 Oct; 12():177. PubMed ID: 23088742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.
    Rovira J; Albarracin G; Salvador L; Rejas J; Sánchez-Iriso E; Cabasés JM
    Community Ment Health J; 2012 Jun; 48(3):372-83. PubMed ID: 22484993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and costs in patients with generalised anxiety disorder: one-year retrospective analysis of data from national registers in Sweden.
    Sandelin R; Kowalski J; Ahnemark E; Allgulander C
    Eur Psychiatry; 2013 Feb; 28(2):125-33. PubMed ID: 22542328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
    Bereza BG; Machado M; Einarson TR
    Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.
    Carrasco JL; Álvarez E; Olivares JM; Rejas J
    Actas Esp Psiquiatr; 2013; 41(3):164-74. PubMed ID: 23803800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder.
    Berger A; Mychaskiw M; Dukes E; Edelsberg J; Oster G
    BMC Geriatr; 2009 Jul; 9():31. PubMed ID: 19635161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study.
    Berger A; Edelsberg J; Teal S; Mychaskiw MA; Oster G
    BMC Pulm Med; 2012 Dec; 12():75. PubMed ID: 23231890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical research practice datalink analysis of antidepressant treatment patterns and health care costs in generalized anxiety disorder.
    Chollet J; Saragoussi D; Clay E; François C
    Value Health; 2013 Dec; 16(8):1133-9. PubMed ID: 24326166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
    De Salas-Cansado M; Álvarez E; Olivares JM; Carrasco JL; Ferro MB; Rejas J
    Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.
    Uhlenhuth EH; Balter MB; Ban TA; Yang K
    Depress Anxiety; 1999; 9(3):107-16. PubMed ID: 10356648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder.
    Zhu B; Zhao Z; Ye W; Marciniak MD; Swindle R
    J Nerv Ment Dis; 2009 Feb; 197(2):136-9. PubMed ID: 19214050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidities and associated treatment charges in patients with anxiety disorders.
    McLaughlin T; Geissler EC; Wan GJ
    Pharmacotherapy; 2003 Oct; 23(10):1251-6. PubMed ID: 14594343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
    Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of generalized anxiety disorder.
    Davidson JR
    J Clin Psychiatry; 2001; 62 Suppl 11():46-50; discussion 51-2. PubMed ID: 11414551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.